LUMOS PHARMA INC's ticker is LUMO and the CUSIP is 55028X109. A total of 38 filers reported holding LUMOS PHARMA INC in Q2 2024. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $59,764 | -17.7% | 25,760 | 0.0% | 0.01% | -23.1% |
| Q1 2024 | $72,644 | -11.3% | 25,760 | 0.0% | 0.01% | -13.3% |
| Q4 2023 | $81,917 | -3.6% | 25,760 | 0.0% | 0.02% | -25.0% |
| Q3 2023 | $85,008 | -17.1% | 25,760 | -17.1% | 0.02% | -20.0% |
| Q2 2023 | $102,591 | -0.3% | 31,088 | 0.0% | 0.02% | -7.4% |
| Q1 2023 | $102,902 | +35.6% | 31,088 | +47.9% | 0.03% | +22.7% |
| Q4 2022 | $75,882 | -35.7% | 21,020 | +57.9% | 0.02% | -40.5% |
| Q3 2022 | $118,000 | +14.6% | 13,315 | 0.0% | 0.04% | +27.6% |
| Q2 2022 | $103,000 | -17.6% | 13,315 | 0.0% | 0.03% | 0.0% |
| Q1 2022 | $125,000 | +35.9% | 13,315 | 0.0% | 0.03% | +52.6% |
| Q4 2021 | $92,000 | -27.0% | 13,315 | +0.6% | 0.02% | -32.1% |
| Q3 2021 | $126,000 | +41.6% | 13,234 | +48.4% | 0.03% | +40.0% |
| Q2 2021 | $89,000 | – | 8,919 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 407,192 | $14,540,000 | 2.80% |
| Opaleye Management Inc. | 281,287 | $10,045,000 | 1.31% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 936,291 | $33,435,000 | 0.66% |
| NEA Management Company, LLC | 526,663 | $18,807,000 | 0.50% |
| Investors Financial Group, LLC | 18,200 | $650,000 | 0.43% |
| One68 Global Capital, LLC | 5,855 | $209,000 | 0.42% |
| Wealth Advisors of Iowa, LLC | 11,760 | $420,000 | 0.26% |
| Blackstone Inc. | 468,145 | $16,717,000 | 0.06% |
| Foster Group, Inc. | 7,283 | $221,000 | 0.04% |
| Texas Yale Capital Corp. | 16,000 | $571,000 | 0.04% |